Agomab outlines design of phase 2b NOV‑ERA study in fibrostenosing Crohn’s disease
FDA alignment secured as company prepares to begin dosing in 2026
Read the full article on the original site.
Read Full Article
FDA alignment secured as company prepares to begin dosing in 2026
Read the full article on the original site.
Read Full Article